Rulonilimab

洛奈利单抗

Report date: 2025/01/14 15:50:26

Base Information

Drug NameRulonilimab
Drug Alias Name重组人源化抗PD-1单克隆抗体注射液 (山东新时代药业)F-520
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaUterine Cervical Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShandong New Time Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong New Time Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsCentral Nervous System LymphomaCarcinoma, Transitional CellLymphoma, T-Cell, Peripheral +[5] 

Other Information

ATC CodeN/A
Related LinksN/A